Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmaxis initiates phase III trial in lung disease
Bronchiectasis is an incurable, degenerative and chronic inflammatory condition of the lungs affecting more than half a million people worldwide. The trial, which will investigate the safety and
Bronchiectasis is an incurable, degenerative and chronic inflammatory condition of the lungs affecting more than half a million people worldwide. The trial, which will investigate the safety and
Bio-E-Gel is a gel formulation of estradiol, the same estrogen produced naturally in women, developed to be quickly absorbed through the skin after topical application on the upper
Aida will purchase an additional 45% of the outstanding shares of Shanghai Qiaer for $495,650. Aida previously paid $561,324 as a deposit to purchase 55% of the shares
The company is developing a commercial genetic test using this newly validated research, which it expects to launch before the end of the year. Such a test has
This orphan drug program is assessing the efficacy and safety of the company’s Interleukin-1 (IL-1) trap in adult patients with these diseases. The trial will include a six-month,
Asuragen, a newly formed molecular diagnostic company and formerly a division of Ambion, has received an up-front payment from Digene and will receive additional payments based on regulatory
This study is a double-blind, placebo-controlled, randomized, outpatient clinical investigation in adult patients with moderate-to-severe chronic plaque psoriasis. Each patient receives double-blind treatment for 12 weeks, with a
“Bayer's proposal has been carefully examined considering the interests of all stakeholders. It includes a fair price and additional important commitments. Therefore we are convinced that it is
This designation is based on a recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA). “This orphan medicinal product designation demonstrates the
The trial will evaluate the drug in combination with rituximab in patients with relapsed or refractory follicular lymphoma, a subtype of non-Hodgkin’s lymphoma (NHL). This study builds on